Abbott Labs Gets FDA Approval for Amplatzer Piccolo Occluder
January 14 2019 - 9:51AM
Dow Jones News
By Colin Kellaher
Abbott Laboratories (ABT) in Monday said the U.S. Food and Drug
Administration approved the Amplatzer Piccolo Occluder for the
treatment of a common congenital heart defect in premature babies
and newborns.
The Abbott Park, Ill., maker of health-care products said the
Amplatzer Piccolo is the first and only minimally invasive,
transcatheter treatment specifically approved for premature babies
with patent ductus arteriosus, a life-threatening opening in the
heart.
Abbott said the occluder, which can be implanted in babies
weighing as little as two pounds, is a self-expanding, wire mesh
device tinier than a small pea that is used to seal the opening in
the heart.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 14, 2019 09:36 ET (14:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Sep 2023 to Sep 2024
